Clusterin silencing restores myoblasts viability and down modulates the inflammatory process in osteoporotic disease

S. Pucci; C. Greggi; C. Polidoro; M. C. Piro; M. Celi; M. Feola; E. Gasbarra; R. Iundusi; F. Mastrangeli; G. Novelli; A. Orlandi; U. Tarantino

doi:10.1186/s12967-019-1868-5

Journal of Translational Medicine (Apr 2019)

Clusterin silencing restores myoblasts viability and down modulates the inflammatory process in osteoporotic disease

S. Pucci,
C. Greggi,
C. Polidoro,
M. C. Piro,
M. Celi,
M. Feola,
E. Gasbarra,
R. Iundusi,
F. Mastrangeli,
G. Novelli,
A. Orlandi,
U. Tarantino

Affiliations

S. Pucci: Department of Biomedicine and Prevention, Tor Vergata University of Rome
C. Greggi: Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata
C. Polidoro: Department of Biomedicine and Prevention, Tor Vergata University of Rome
M. C. Piro: Department of Experimental Medicine and Surgery, University of Rome “Tor Vergata”
M. Celi: Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata
M. Feola: Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata
E. Gasbarra: Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata
R. Iundusi: Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata
F. Mastrangeli: Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata
G. Novelli: Department of Biomedicine and Prevention, Tor Vergata University of Rome
A. Orlandi: Department of Biomedicine and Prevention, Tor Vergata University of Rome
U. Tarantino: Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata

DOI: https://doi.org/10.1186/s12967-019-1868-5
Journal volume & issue: Vol. 17, no. 1
pp. 1 – 16

Abstract

Read online

Abstract Background Targeting new molecular pathways leading to Osteoporosis (OP) and Osteoarthritis (OA) is a hot topic for drug discovery. Clusterin (CLU) is a glycoprotein involved in inflammation, proliferation, cell death, neoplastic disease, Alzheimer disease and aging. The present study focuses on the expression and the role of CLU in influencing the decrease of muscle mass and fiber senescence in OP-OA condition. Methods Vastus lateralis muscle biopsies were collected from 20 women with OP undergoing surgery for fragility hip fracture and 20 women undergoing arthroplasty for hip osteoarthritis. Results We found an overexpression of CLU in degenerated fibers in OP closely correlated with interleukin 6 (IL6) and histone H4 acetylation level. Conversely, in OA muscle tissues we observed a weak expression of CLU but no nuclear histone H4 acetylation. Ex vivo studies on isolated human myoblasts confirmed CLU overexpression in OP as compared to OA (p < 0.001). CLU treatment of isolated OP and OA myoblasts showed: modulation of proliferation, morphological changes, increase of histone H4 acetylation and induction of myogenin (MYOG) activation in OP myoblast only. In OP condition, functional knockdown of CLU by siRNA restores proliferative myoblasts capability and tissue damage repair, carried out by an evident upregulation of Transglutaminase 2 (TGM2). We also observed downmodulation of CX3CR1 expression with consequent impairing of the inflammatory infiltrate recruitment. Conclusions Results obtained suggest a potential role of CLU in OP by influencing myoblasts terminal differentiation, epigenetic regulation of muscle cell differentiation and senescence. Moreover, CLU silencing points out its role in the modulation of tissue damage repair and inflammation, proposing it as a new diagnostic marker for muscle degeneration and a potential target for specific therapeutic intervention in OP related sarcopenia.

Published in Journal of Translational Medicine

ISSN: 1479-5876 (Online)
Publisher: BMC
Country of publisher: United Kingdom
LCC subjects: Medicine
Website: https://translational-medicine.biomedcentral.com/

About the journal

Abstract

Keywords